| |
| Drug Development Committee >> Heike Wulff |
 |
| |
 |
Heike Wulff, PhD
|
|
| |
| |
Assistant Professor, Medical Pharmacology and Toxicology at the University of California, Davis. Dr. Wulff is the world’s foremost authority on the pharmaceutical chemistry of PAP-1 and its derivatives. Dr. Wulff carried out her postdoctoral research in Dr. Chandy’s laboratory at the University of California, Irvine, where she demonstrated that myelin-reactive disease-causing T cells from patients with MS exhibit a unique Kv1.3-high expression pattern. She has authored 25 peer-reviewed papers, is co-inventor on 6 patents. Dr. Wulff is an Airmid co-founder. Dr. Wulff’s PhD in Pharmaceutical Chemistry is from the University of Kiel, Germany.
|
| |
|
|
 |
|
| February 2011 |
| February 2011 AIRMID partners with Circassia to develop topical PAP-1 |
|
| January 2010 |
| Joe Sum joins
AIRMID Board of Directors |
| July 2009 |
AIRMID partners with Kineta
to develop ShK peptides
|
|
more... |
|
